Related resources
Full-text held externally
- DOI: 10.1093/jnci/djn269
Search for item elsewhere
University researcher(s)
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Gurwitz D, Newman WG
J Natl Cancer Inst. 2008;100( 18).
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- DOI: 10.1093/jnci/djn269
Keyword(s)
Chemotherapy, Adjuvant; Decision Making; Disease-Free Survival; Female; Genotype; Humans; Markov Chains; Middle Aged; Patient Participation; Postmenopause; drug therapy: Breast Neoplasms; genetics: Cytochrome P-450 CYP2D6; pharmacokinetics: Antineoplastic Agents, Hormonal; pharmacokinetics: Aromatase Inhibitors; pharmacokinetics: Estrogen Receptor Modulators; pharmacokinetics: Nitriles; pharmacokinetics: Tamoxifen; pharmacokinetics: Triazoles; statistics & numerical data: Asian Continental Ancestry Group